Abstract
Bispecific antibodies (BsAbs) are thought to have a promising clinical application and many R&D companies include them in their R&D pipeline. We tried to analyze the technology flows pattern of BsAbs by patent citation network, then identified technological opportunities and risks of different drug targets for R&D companies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
